Jeff Yass’s Voyager Therapeutics VYGR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $51.5K | Sell |
14,700
-20,700
| -58% | -$78.5K | ﹤0.01% | 12816 |
|
|
2026
Q1 | $137K | Buy |
35,400
+19,900
| +128% | +$78.3K | ﹤0.01% | 12105 |
|
|
2025
Q4 | $60.9K | Sell |
15,500
-700
| -4% | -$3.1K | ﹤0.01% | 11686 |
|
|
2025
Q3 | $75.7K | Sell |
16,200
-6,500
| -29% | -$23.5K | ﹤0.01% | 11705 |
|
|
2025
Q2 | $70.6K | Buy |
+22,700
| New | +$73.2K | ﹤0.01% | 11986 |
|
|
2025
Q1 | – | Sell |
-37,400
| Closed | -$212K | – | 13557 |
|
|
2024
Q4 | $212K | Buy |
37,400
+11,600
| +45% | +$74.8K | ﹤0.01% | 10609 |
|
|
2024
Q3 | $151K | Buy |
25,800
+5,400
| +26% | +$39.3K | ﹤0.01% | 10738 |
|
|
2024
Q2 | $161K | Sell |
20,400
-16,500
| -45% | -$138K | ﹤0.01% | 10612 |
|
|
2024
Q1 | $344K | Buy |
36,900
+19,600
| +113% | +$165K | ﹤0.01% | 9394 |
|
|
2023
Q4 | $146K | Sell |
17,300
-40,800
| -70% | -$296K | ﹤0.01% | 11001 |
|
|
2023
Q3 | $450K | Buy |
58,100
+31,100
| +115% | +$284K | ﹤0.01% | 8482 |
|
|
2023
Q2 | $309K | Sell |
27,000
-131,000
| -83% | -$1.36M | ﹤0.01% | 9374 |
|
|
2023
Q1 | $1.22M | Buy |
+158,000
| New | +$1.26M | ﹤0.01% | 6295 |
|
|
2022
Q4 | – | Sell |
-55,300
| Closed | -$327K | – | 13805 |
|
|
2022
Q3 | $327K | Sell |
55,300
-15,500
| -22% | -$99.2K | ﹤0.01% | 9574 |
|
|
2022
Q2 | $418K | Sell |
70,800
-6,900
| -9% | -$46.6K | ﹤0.01% | 8715 |
|
|
2022
Q1 | $592K | Sell |
77,700
-27,400
| -26% | -$122K | ﹤0.01% | 8535 |
|
|
2021
Q4 | $285K | Buy |
105,100
+86,300
| +459% | +$294K | ﹤0.01% | 10610 |
|
|
2021
Q3 | $49K | Sell |
18,800
-26,600
| -59% | -$86.4K | ﹤0.01% | 12355 |
|
|
2021
Q2 | $188K | Sell |
45,400
-106,500
| -70% | -$483K | ﹤0.01% | 11658 |
|
|
2021
Q1 | $715K | Buy |
151,900
+74,700
| +97% | +$509K | ﹤0.01% | 8603 |
|
|
2020
Q4 | $552K | Buy |
+77,200
| New | +$742K | ﹤0.01% | 8068 |
|
|
2019
Q3 | – | Sell |
-21,700
| Closed | -$591K | – | 10915 |
|
|
2019
Q2 | $591K | Buy |
21,700
+6,000
| +38% | +$137K | ﹤0.01% | 6928 |
|
|
2019
Q1 | $300K | Buy |
+15,700
| New | +$205K | ﹤0.01% | 7214 |
|
|
2018
Q4 | – | Sell |
-27,700
| Closed | -$524K | – | 10076 |
|
|
2018
Q3 | $524K | Sell |
27,700
-6,300
| -19% | -$121K | ﹤0.01% | 6430 |
|
|
2018
Q2 | $664K | Sell |
34,000
-34,300
| -50% | -$678K | ﹤0.01% | 6235 |
|
|
2018
Q1 | $1.28M | Buy |
68,300
+1,900
| +3% | +$41.1K | ﹤0.01% | 4734 |
|
|
2017
Q4 | $1.1M | Buy |
+66,400
| New | +$1.14M | ﹤0.01% | 5028 |
|
Other funds holding VYGR
AC
VPC
OM
Jeff Yass's VYGR Position: Q2 2026 in Review
Jeff Yass increased its Voyager Therapeutics (VYGR) stake by 15% in Q2 2026, buying an estimated $45.5K and bringing the position to 90,899 shares worth $318K. The position accounts for ﹤0.01% of the portfolio, ranked #10912.
Jeff Yass first reported a position in VYGR in Q4 2016 and has held it in 32 quarters since. The position peaked at $2.48M in Q1 2023. 135 funds tracked by Wall St. Rank hold VYGR as of Q2 2026.
- Jeff Yass held 90,899 shares of Voyager Therapeutics worth $318K as of Q2 2026.
- Jeff Yass bought 12,008 Voyager Therapeutics shares in Q2 2026, an estimated $45.5K.
- Voyager Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10912 holding.
- Jeff Yass first reported a position in Voyager Therapeutics in Q4 2016 and has held it in 32 quarters since.
- Jeff Yass's Voyager Therapeutics position peaked at $2.48M in Q1 2023.
- 135 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2026.
Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.